Ambitious Danish biotech fund shuts down before first investment

Ambitions were high when Sund Capital, headed by the former Zealand Pharma CEO David Solomon, announced plans to raise up to DKK 2 billion (EUR 268 million) for investments in up-and-coming biotechs. But now the fund is closing down.

Former Zeland Pharma CEO David Solomon was co-founder of the venture fund Sund Capital

With a total loss of DKK 2.9 million after 18 months, the end has come for Sund Capital which was founded in summer 2016 with the aim of investing up to DKK 2.2 billion in Nordic biotechs.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

AMWatch finds new editor in own ranks

After four years as editor of AMWatch, Søren Rathlou Top is leaving the media for a press coordinator role. Anne Louise Houmann is taking over the reins.

ATP nears end point of historic restructuring

New opportunities to allocate more to riskier assets mean changes are being made at ATP. A restructuring of the central IT system has been the toughest nut to crack in the restructuring, which has been described as the most comprehensive change in the pension giant’s 60-year history.

Further reading

Latest news

AMWatch job

See all jobs

See all jobs

Watch job

See all jobs

See all jobs

Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch